Results 61 to 70 of about 12,561 (177)

Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial

, 2023
Objective: Early warfarin anticoagulation is recommended in patients undergoing surgical bioprosthetic valve implantation or valve repair. It is unclear whether non-vitamin K antagonist oral anticoagulants can be a full alternative to warfarin.
이삭, 서지원, 이찬주, 김영진, 홍그루, 심지영, 서영주, 이승현, 하종원, 신동호, De Caterina R., Lee S., Hong G. -R., Shim C. Y., Seo J., Lee S. H., Choi J. Y., Suh Y. J., Roh Y. H., Shin D. -H., Cho I. -J., Lee C. J., Ha J. -W., Kim Y. J., Yun Ho Roh, Jiwon Seo, Dong-Ho Shin, Sak Lee, Chan Joo Lee, Jong-Won Ha, Geu-Ru Hong, Raffaele De Caterina, Chi Young Shim, Seung Hyun Lee, Young Joo Suh, Jah Yeon Choi, In-Jeong Cho, Young Jin Kim   +37 more
core   +1 more source

Clinical outcomes in patients receiving edoxaban or phenprocoumon for prevention of stroke in atrial fibrillation: a German real-world cohort study

Thrombosis Journal, 2022
Background Appropriate and timely anticoagulant therapy with vitamin K antagonists (VKAs) or non-vitamin K oral antagonists (NOACs) is essential for stroke prevention in non-valvular atrial fibrillation (NVAF).
Christopher Hohmann, Magnus Lutz, Sheila Vignali, Kathrin Borchert, Karolin Seidel, Sebastian Braun, Stephan Baldus, Michael Näbauer   +7 more
doaj   +1 more source

Do We Really Know How to Manage Anticoagulated Patients for Periodontal Nonsurgical Therapy? An Observational Cohort Study

International Journal of Dental Hygiene, EarlyView.
ABSTRACT Objectives The aim of this work is to assess and compare the impact of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKA) during and immediately after periodontal nonsurgical therapy. Materials and Methods A prospective observational cohort study was conducted with patients who presented a history of cardiovascular disease ...
F. Berton, A. Rapani, F. Costantinides, V. Nicolin, D. Cuhureanu, R. Di Lenarda   +5 more
wiley   +1 more source

Table1_Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation.DOCX

, 2021
Background and Purpose: Edoxaban exposure varies across different ethnicities. The purpose of our study was to examine the risk factors associated with high or low edoxaban concentrations in Asian populations.Methods: Participants with atrial ...
Shin-Yi Lin (225316), Jiann-Shing Jeng (125224), Sung-Chun Tang (81377), Ching-Hua Kuo (523495), Chih-Fen Huang (5007860), Li-Ting Ho (700378), Yen-Bin Liu (514954)   +6 more
core   +1 more source

Refining Residual Ischemic Stroke Risk in Anticoagulated Atrial Fibrillation Using Index Outpatient LA Diameter: The CHA2DS2‐VALa Score

Journal of Cardiovascular Electrophysiology, EarlyView.
In anticoagulated atrial fibrillation, residual ischemic stroke risk persists despite guideline‐directed therapy. In this single‐center cohort, an enlarged index outpatient left atrial diameter independently predicted stroke and improved risk stratification when added to CHA2DS2‐VA (CHA2DS2‐VALa), supporting a simple, clinically implementable ...
Sefa Erdi Ömür, Emin Koyun, Gülşen Genç Tapar, Kayıhan Karaman, Metin Karayakali, Ataç Çelik, Uğur Kulu, Yasin Taşkin   +7 more
wiley   +1 more source

Edoxaban (LIXIANA®) in the treatment of venous thromboembolism

, 2021
Standard therapy for venous thromboembolism (VTE) includes the use of heparins and vitamin K antagonists. Randomized clinical trials have shown that non-vitamin K oral anticoagulants are as effective and safe as standard therapy in VTE treatment, with an
Carbone A., Russo V., Spaccarotella C., Golino P., Rago A., D'Andrea A., Papa A. A., Nigro G., Bottino R., Liccardo B.   +9 more
core   +1 more source

Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban‐treated patients and healthy controls

Research and Practice in Thrombosis and Haemostasis, 2022
Introduction The activated partial thromboplastin time (aPTT) and the prothrombin time (PT) are widely available coagulation parameters which are however poor predictors of the anticoagulant effect of direct oral anticoagulants (DOACs).
Jonathan Evrard, Romain Siriez, Céline Bouvy, Julien Favresse, Halil Yildiz, Philippe Hainaut, François Mullier, Jean‐Michel Dogné, Jonathan Douxfils   +8 more
doaj   +1 more source

Variation in Anticoagulation Practice for Atrial High‐Rate Episodes: A Nationwide Cross‐Sectional Survey

Journal of Cardiovascular Electrophysiology, EarlyView.
ABSTRACT Background Atrial high‐rate episodes (AHRE) detected by cardiac implantable electronic devices (CIEDs) are associated with increased thromboembolic risk, yet their clinical significance and optimal anticoagulation strategy remain uncertain, particularly in the absence of electrocardiogram (ECG)‐confirmed atrial fibrillation.
Kyi Zin Thant, Ibrahim Antoun, Kaung Myat Thu, Riyaz Somani, Zakariyya Vali, G. Andre Ng, Mokhtar Ibrahim   +6 more
wiley   +1 more source

Correlation between blood loss and pharmacodynamic markers in edoxaban-anticoagulated rabbits.

, 2018
Blood loss correlated with (A) anti-FXa activity and (B) unbound edoxaban plasma concentrations. Each data point represents the measurements from an individual rabbit at the end of andexanet infusion (Time 25 minutes) for anti-FXa and unbound edoxaban ...
Janet M. Leeds (346149), John Malinowski (5029931), Polly Pine (5029946), Stanley J. Hollenbach (2720365), Joyce Lin (5029937), John T. Curnutte (5029940), Francis DeGuzman (5029934), Pratikhya Pratikhya (235082), Genmin Lu (5029949), Pamela B. Conley (5029943)   +9 more
core   +1 more source

The DOAC‐FRAIL Study—Same Dose, Different Story: Prevalence of Deviant Direct Oral Anticoagulant Levels in Nursing Home Residents

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Direct oral anticoagulants (DOACs) are prescribed using fixed dosing regimens, despite limited evidence on their pharmacokinetic behavior in nursing home residents. Participants and Setting One hundred nursing home residents are receiving apixaban, rivaroxaban, dabigatran, or edoxaban in multiple long‐term care facilities in the ...
Irme S. Franssen, Melanie J. de Jong, Lars Visseren, Daan Teerds, Dave Hellenbrand, Yvonne Henskens, Henri Spronk, Daisy J. A. Janssen, Dionne C. W. Braeken, Sander M. J. van Kuijk, Kristien Winckers, Fabienne J. H. Magdelijns   +11 more
wiley   +1 more source